A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants

NCT04366349 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Asthma

Interventions

BIOLOGICAL: melrilimab (GSK3772847) 70 milligram (mg)
BIOLOGICAL: melrilimab (GSK3772847) 140 milligram (mg)
OTHER: Placebo

Sponsor

GlaxoSmithKline